Cholesterol-lowering therapy for primary prevention: still much we don't know

Editorial

Lee A Green. Arch Intern Med. 2010.

. 2010 Jun 28;170(12):1007-8.

doi: 10.1001/archinternmed.2010.168.

No abstract available

Comment in

Trials by independent expert bodies.
Breimer LH, Mikhailidis DP. Breimer LH, et al. Arch Intern Med. 2010 Dec 13;170(22):2042; author reply 2043-4. doi: 10.1001/archinternmed.2010.457. Arch Intern Med. 2010. PMID: 21149770 No abstract available.

Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants.
Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Ray KK, et al. Arch Intern Med. 2010 Jun 28;170(12):1024-31. doi: 10.1001/archinternmed.2010.182. Arch Intern Med. 2010. PMID: 20585067 Review.
Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, Okuyama H, Pavy B, Rabaeus M. de Lorgeril M, et al. Arch Intern Med. 2010 Jun 28;170(12):1032-6. doi: 10.1001/archinternmed.2010.184. Arch Intern Med. 2010. PMID: 20585068 Review.